Pharmaceutical composition containing ibrutinib

A technology of ibrutinib and composition, applied in the field of pharmaceutical preparation, can solve the problems of propylene glycol dosage limitation, safety problems, etc., and achieve the effects of excellent emulsification, good low-temperature washing performance and good solubility
CN106619643AInactive Publication Date: 2017-05-10ABA CHEM SHANGHAI
2 Cites 17 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
ABA CHEM SHANGHAI
Publication Date
2017-05-10
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a pharmaceutical composition containing ibrutinib. The pharmaceutical composition is prepared from, by weight, 13-15 parts of ibrutinib, 30-50 parts of solvent, 20-30 parts of solubilizer, 8-12 parts of filler, 6-10 parts of disintegrant and 21-26 parts of officinal organic acid, wherein the solvent is glycerolformal, and the officinal organic acid is a mixture of oleic acid and glyceryl monooleate based on the mass ratio of (1.7-2.1):1. The pharmaceutical composition containing ibrutinib has the advantages that compared with traditional pharmaceutical compositions, the variety of the solvent in the formula is changed, glycerolformal which is high in safety performance serves as the solvent with dosage unlimited, and multiple medicines are soluble in glycerolformal; meanwhile, due to the fact that the officinal organic acid is a mixture of oleic acid and glyceryl monooleate, the pharmaceutical composition containing ibrutinib is more stable and simpler than traditional pharmaceutical compositions adopting single officinal organic acid.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of medicine preparation, in particular to a medicine composition containing ibrutinib. Background technique

[0002] Ibrutinib is a small molecule BTK inhibitor that can covalently bind to the cysteine ​​residue in the active center of BTK, thereby inhibiting its activity. The full name of BTK is Bruton’styrosinekinase, which transmits signals in the BCR signaling pathway and cytokine receptor signaling pathway, and mediates the migration, chemotaxis and adhesion of B cells. Preclinical studies have shown that ibrutinib can inhibit the proliferation and survival of malignant B cells.

[0003] After searching, it was found that the patent CN 105640961 A disclosed a pharmaceutical composition containing ibrutinib, the active component of which is ibrutinib, which is characterized by the selection of medium and long-chain saturated or unsaturated fatty acids, substituted carboxylic acids, etc. The pharmaceuti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More